Hattie Hayes is a journalist specializing in ophthalmology and eye health. She writes for Ophthalmology Times, covering topics such as new technologies in the field, drug approvals, surgical techniques, and industry news. With a focus on providing informative and up-to-date information, Hattie aims to keep readers informed about the latest advancements and trends in ophthalmology.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Hattie Hayes' coverage primarily focuses on the healthcare and pharmaceutical industry, specifically in ophthalmology. She frequently features announcements, press releases, and industry-specific content related to medicines, pharmaceuticals, and scientific developments.
Given her extensive coverage of the European Medicines Agency (EMA) recommendations and safety recalls for medical treatments, Hattie would likely be interested in experts who can provide insights into regulatory changes impacting this sector or those with a deep understanding of specific medications or treatment methods.
As she has a national focus on the United States but covers international topics such as EMA decisions significantly affecting global pharmaceutical markets; pitches should balance providing relevant US perspectives while also acknowledging broader international implications.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Hakan Kaymak, Hattie Hayes
Considering ages and stages of myopia progression in a therapeutic timeline
By: Hattie Hayes, Emily Kaiser Maharjan
The agency approved Yesafili (Biocon Biologics) and Opuviz (Samsung Bioepis, Biogen) as biosimilars to Eylea (Regeneron Pharmaceuticals).
By: Hattie Hayes, Emily Kaiser Maharjan
Aflibercept-jbvf and aflibercept-yszy are the first interchangeable biosimilars to aflibercept 2 mg that have been approved in the US.
Faricimab is already approved in the EU and UK for neovascular age-related macular degeneration and diabetic macular edema.
By: Hattie Hayes
Jennifer I. Lim, MD, FARVO, FASRS, sat down with Sydney M. Crago, Assistant Managing Editor of Ophthalmology Times and Modern Retina, to discuss her ASRS 2024 presentation, "Differential Artery-Vein Analysis Improves OCTA Performance for Artificial Intelligence Classification of Diabetic Retinopathy."
By: Sydney M Crago, Hattie Hayes
Jennifer I. Lim, MD, FARVO, FASRS, discusses her ASRS presentation, "Differential Artery-Vein Analysis Improves OCTA Performance for Artificial Intelligence Classification of Diabetic Retinopathy"
By: Hattie Hayes
This year, the ASRS meeting will feature an expert panel on sustainability — learn more from panelist Martin Zinkernagel, MD, PhD
By: Hattie Hayes
Carl C. Awh, MD, FASRS, gives an overview of the Phase 3 Pagoda trial year 2 results
Carl C Awh, MD, FASRS, sat down with Hattie Hayes, Editor of Ophthalmology Times Europe, to discuss the first readout of the Phase 3 PAGODA trial at the American Society of Retina Specialists meeting held in Stockholm, Sweden.
By: Sydney M Crago, Hattie Hayes
John Thompson, MD, discusses long-term results of using ICG to peel ILM in the treatment of macular holes
(833) 317-6278 
